Hospital Formulary Entry: warfarin

Document Control Information

| Document ID: | MED-PROT-7693 |
|--------------------|-------------------------------|
| Effective Date: | 2024-09-14 |
| Review Date: | 2025-10-14 |
| Therapeutic Class: | High-Priority Clinical Update |
| Risk Level: | Critical |

Standard Dosing Protocol

Current Standard Dose: 5mg daily standard dosing **Monitoring Requirements:** Monitor INR monthly

Administration Guidelines

Route of Administration: Oral Frequency: Three times daily Duration: Until discontinued

Patient Population: Adult patients in acute care settings

Contraindications and Precautions

Contraindications: Standard contraindications apply **Adverse Events:** Enhanced monitoring for adverse effects

Detailed Clinical Considerations

Patient Monitoring Protocol

Regular monitoring is essential for safe administration of warfarin. Current protocols require Monitor INR monthly. Healthcare providers should assess patient response and adjust therapy accordingly. Baseline laboratory values should be obtained prior to initiation. The mechanism of action involves Updated mechanism with safety considerations. Clinical efficacy has been demonstrated in atrial fibrillation.

Special Populations

Elderly Patients: Dose adjustment may be required based on renal function and overall health status.

Pediatric Patients: Safety and efficacy not established in patients under 18 years.

Pregnancy: Use only if potential benefit justifies potential risk to fetus. **Nursing Mothers:** Exercise caution when administering to nursing women.

Last revised: January 2025